Media

AYOXXA appoints permanent CEO

Cologne, December 7, 2016
The Supervisory Board of AYOXXA Biosystems GmbH is pleased to announce that following his initial assumption of the duties of CEO in October 2016, Rodney Turner will continue to lead the company as CEO on a permanent basis effective immediately. The board and Mr. Turner are aligned on the future growth opportunities for AYOXXA which focus on bringing it’s state-of-the-art LUNARIS™ multiplex immunoassay system to users for the first time, and expanding partnerships in the development and use of the platform.

Changes in the AYOXXA Management Team

Cologne, 07.11.2016
The supervisory board of AYOXXA GmbH announces that Mr. Rodney Turner has assumed duties as the interim CEO of AYOXXA effective October 15, 2016. Mr. Turner is pleased to lead the company as its orientation shifts toward market development and product refinement. The supervisory board and the management team wish to thank Dr. Andreas Schmidt for his years of leadership in founding and establishing AYOXXA as a leading biotech start-up in Germany.

AYOXXA and Märzhäuser introduce a benchtop device for Protein Multiplex Analysis

AYOXXA reader AR01 is ready for the market

Cologne, 22.08.2016
AYOXXA Biosystems GmbH, an international biotechnology company, and Märzhäuser Wetzlar GmbH & Co KG, a leading precision equipment manufacturer, joined forces to develop a dedicated benchtop device for the analysis of LUNARIS™ Multiplex assays. The AYOXXA Reader AR01 expands the technology platform to offer researchers a complete, flexible and user-friendly system for multiprotein analysis. The device was approved for routine laboratory work use in biomedical research.

AYOXXA is Member of the International EYE-RISK Consortium

LUNARIS™ multiplexing platform is applied in epidemological studies for AMD

Cologne, October 22nd, 2015 
AYOXXA Biosystems GmbH, an international biotechnology company, is one of two industrial partners of EYE-RISK, a large biomedical consortium bringing together the expertise of ten renown scientific and clinical institutions and a patient organization from six European countries. It is led by Prof. Dr. Marius Ueffing of the University Medical Center of Tübingen, Germany and Prof. Dr. Caroline Klaver of the Erasmus University Medical Center Rotterdam, Netherlands. AYOXXA contributes the LUNARIS™ technology platform to develop biomarker footprints to stratify patient subgroups.

Media Response

>

In the following section, we consolidate articles published about AYOXXA as a service.
They are linked to sources in either online or offline media and therefore are written in German or English language as indicated.

Enjoy Reading!

07.11. 2016

Global Pharma Update

AYOXXA Biosystem announced changes in management team

The supervisory board of AYOXXA Biosystems GmbH announces that Mr. Rodney Turner has assumed duties as the interim CEO of AYOXXA effective October 15, 2016. Mr. Turner is pleased to lead the company as its orientation shifts toward market development and product refinement. The supervisory board and the management team wish to thank Dr. Andreas Schmidt for his years of leadership in founding and establishing AYOXXA as a leading biotech start-up in Germany. Dr. Schmidt has stepped down from his position as CEO, though he will remain associated with the company. Mr. Turner and Dr. Markus Zumbansen (CTO) were formally registered as managing directors of the company effective October 15, 2016.

16.06. 2016

CELL

A Long Noncoding RNA lincRNA-EPS Acts as a Transcriptional Brake to Restrain Inflammation

CELL Volume 165 (7): 1672-1685 "A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation"
Peer reviewed scientific publication by Maninjay K. Atianand et al.

more

Corresponding author:
Katherine A. Fitzgerald, PhD
Program in Innate Immunity; Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA Link to website

02.06. 2016

Bonner General Anzeiger

Ausländische Investoren suchen deutsche Start-ups

High-Tech Gründerfonds bringt in Bonn Geldgeber und Unternehmer zusammen. Seit 2005 hat der Fonds in mehr als 400 Unternehmen aus der High-Tech-Branche investiert.

Molekularbiologe Andreas Schmidt hat den Weg geschafft: Heraus aus dem Forschungslabor hinein in die freie Wirtschaft. Vor gut sechs Jahren gründete er mit einem Partner in Köln die Firma Ayoxxa. Mittlerweile ist das junge Biotechnologie-Unternehmen auch mit Standorten in Singapur und in den USA vertreten. Die Kölner haben eine Technologie entwickelt, die es ermöglicht, unterschiedliche Proteine simultan zu analysieren. Diese neuartigen Biochips finden Anwendung in pharmakologischen Tests und in der biomedizinischen Forschung.

LINK zur  HTGF Webseite